AKT activation predicts outcome in breast cancer patients treated with tamoxifen

Abstract

Oestrogen receptor (ERα) expression is a strong predictor of response to endocrine therapy. The PI3K/AKT/mTOR signal transduction pathway has been implicated in endocrine resistance in vitro. The present study was carried out to test the hypothesis that AKT activation mediates tamoxifen resistance in clinical breast cancer. Immunohistochemistry (IHC) using AKT1‐3, pan‐AKT, pAKT (Thr‐308), pAKT (Ser‐473), pER (Ser‐167), and pHER2 antibodies was performed on 402 ERα‐positive breast carcinomas from patients treated with tamoxifen. High pAKT (Ser‐473) activity (p = 0.0406) and low AKT2 expression (p = 0.0115) alone, or in combination [high pAKT (Ser‐473)/low AKT2; ‘high‐risk’ patient group] (p = 0.0014), predicted decreased overall survival in tamoxifen‐treated patients with ERα‐positive breast cancers. There was no significant association between tumour levels of AKT expression or activity and disease‐free survival (DFS); however, the ‘high‐risk’ patient group was significantly more likely to relapse (p = 0.0491). During tamoxifen treatment, neither AKT2 nor pAKT predicted DFS. Finally, activation of AKT, via phosphorylation, was linked to activation of both HER2 and ERα in this patient cohort. The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERα‐positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance. Patients with a ‘high‐risk’ expression profile were at increased risk of death (hazard ratio 3.22, p = 0.002) relative to ‘low‐risk’ patients, highlighting the potential that tumour profiling, with multiple IHC markers predictive of therapeutic response, may improve patient selection for endocrine therapies, eg tamoxifen or aromatase inhibitor‐based treatments. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.